This study is a multi-center, randomized, open-label, double-blind, positive-controlled phase II clinical study evaluating the efficacy and safety of different doses of SHR2285 tablets vs. enoxaparin for the prevention of postoperative venous thromboembolism in patients undergoing elective unilateral total knee arthroplasty.
|Condition||Prevention of Venous Thrombosis After TKA|
|Treatment||Enoxaparin, SHR2285 tablet|
|Clinical Study Identifier||NCT05203705|
|Sponsor||Shanghai Hengrui Pharmaceutical Co., Ltd.|
|Last Modified on||7 April 2022|
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
No annotations made yet
Congrats! You have your own personal workspace now.